Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan R Davidson

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Journal of Molecular Biology|September 10, 2010
The solution structure of the C-terminal Ig-like domain of the bacteriophage λ tail tube proteinLisa G Pell, Genevieve M C Gasmi-Seabrook, Marc Morais, et al.
Mbio|December 6, 2018
Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR ProteinsJooyoung Lee, Aamir Mir, Alireza Edraki, et al.
Cell|March 25, 2017
Structure Reveals Mechanisms of Viral Suppressors that Intercept a CRISPR RNA-Guided Surveillance ComplexSaikat Chowdhury, Joshua Carter, MaryClare F Rollins, et al.
Cell Reports|November 14, 2019
Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome EditingBianca Garcia, Jooyoung Lee, Alireza Edraki, et al.
Nature|February 4, 2026
A pore-forming antiphage defence is activated by oligomeric phage proteinsPramalkumar H Patel, Matthew R McCarthy, Véronique L Taylor, et al.
Molecular Cell|January 7, 2021
A phage-encoded anti-activator inhibits quorum sensing in Pseudomonas aeruginosaMegha Shah, Véronique L Taylor, Diane Bona, et al.
Nature Communications|June 28, 2019
Inhibition of CRISPR-Cas9 ribonucleoprotein complex assembly by anti-CRISPR AcrIIC2Annoj Thavalingam, Zhi Cheng, Bianca Garcia, et al.
Human Gene Therapy|May 8, 2024
CRISPR-Cas Genome Editing in <i>Ex Vivo</i> Human Lungs to Rewire the Translational Path of Genome-Targeting TherapeuticsKumi Mesaki, Haruchika Yamamoto, Stephen Juvet, et al.
Cell|August 29, 2017
A Broad-Spectrum Inhibitor of CRISPR-Cas9Lucas B Harrington, Kevin W Doxzen, Enbo Ma, et al.
International Journal of Antimicrobial Agents|September 10, 2025
Results of TOR001: An open-label single patient study using targeted bacteriophage therapy for the treatment of chronic urinary tract infectionJonathan D Cook, Payton B Hooey, Keiko C Salazar, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Journal of Molecular Biology|September 10, 2010
The solution structure of the C-terminal Ig-like domain of the bacteriophage λ tail tube proteinLisa G Pell, Genevieve M C Gasmi-Seabrook, Marc Morais, et al.
Mbio|December 6, 2018
Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR ProteinsJooyoung Lee, Aamir Mir, Alireza Edraki, et al.
Cell|March 25, 2017
Structure Reveals Mechanisms of Viral Suppressors that Intercept a CRISPR RNA-Guided Surveillance ComplexSaikat Chowdhury, Joshua Carter, MaryClare F Rollins, et al.
Cell Reports|November 14, 2019
Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome EditingBianca Garcia, Jooyoung Lee, Alireza Edraki, et al.
Nature|February 4, 2026
A pore-forming antiphage defence is activated by oligomeric phage proteinsPramalkumar H Patel, Matthew R McCarthy, Véronique L Taylor, et al.
Molecular Cell|January 7, 2021
A phage-encoded anti-activator inhibits quorum sensing in Pseudomonas aeruginosaMegha Shah, Véronique L Taylor, Diane Bona, et al.
Nature Communications|June 28, 2019
Inhibition of CRISPR-Cas9 ribonucleoprotein complex assembly by anti-CRISPR AcrIIC2Annoj Thavalingam, Zhi Cheng, Bianca Garcia, et al.
Human Gene Therapy|May 8, 2024
CRISPR-Cas Genome Editing in <i>Ex Vivo</i> Human Lungs to Rewire the Translational Path of Genome-Targeting TherapeuticsKumi Mesaki, Haruchika Yamamoto, Stephen Juvet, et al.
Cell|August 29, 2017
A Broad-Spectrum Inhibitor of CRISPR-Cas9Lucas B Harrington, Kevin W Doxzen, Enbo Ma, et al.
International Journal of Antimicrobial Agents|September 10, 2025
Results of TOR001: An open-label single patient study using targeted bacteriophage therapy for the treatment of chronic urinary tract infectionJonathan D Cook, Payton B Hooey, Keiko C Salazar, et al.
Pageof 13